John Chiminski
Chair and Chief Executive Officer at Catalent Pharma Solutions
Meet John Chiminski
“Despite the rise in biologic-based medicines, we cannot forget the vital role that small molecule drugs continue to play in the treatment of so many conditions. These drugs, however, are now often more complex than ever and bring new challenges to drug developers and formulators, especially in the areas of bioavailability, differentiation and patient centricity. The future lies in finding new ways to formulate and deliver complex molecules, and in designing dose forms that are effective and that foster patient acceptance.
The industry has a responsibility to not only talk about patient centricity, but to actually develop drugs that facilitate patient acceptance and adherence to improve outcomes. We need to be using advanced technologies to design new dose forms that are easier to swallow, that can reduce the frequency of administration, and minimize food effects, so that patients’ lives are not necessarily dictated by their drug regimens.”